Real-Life Management of Central and Branch Retinal Vein Occlusion: A Seven-Year Follow-Up Study

Alessandro Arrigo; Anna Crepaldi; Chiara Viganò; Emanuela Aragona; Rosangela Lattanzio; Giovanni Scalia; Antonio Giordano Resti; Francesca Calcagno; Adelaide Pina; Hassan Farah Rashid; Francesco Bandello; Maurizio Battaglia Parodi

doi:10.1055/s-0041-1725197

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2021; 121(10): 1361-1366
DOI: 10.1055/s-0041-1725197

Stroke, Systemic or Venous Thromboembolism

Real-Life Management of Central and Branch Retinal Vein Occlusion: A Seven-Year Follow-Up Study

Alessandro Arrigo

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

,

Anna Crepaldi

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

,

Chiara Viganò

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

,

Emanuela Aragona

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

,

Rosangela Lattanzio

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

,

Giovanni Scalia

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

,

Antonio Giordano Resti

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

,

Francesca Calcagno

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

,

Adelaide Pina

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

,

Hassan Farah Rashid

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

,

Francesco Bandello

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

,

Maurizio Battaglia Parodi

¹Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy

› Institutsangaben

Abstract

Retinal vein occlusion is the second most common retinal vascular pathology after diabetic retinopathy and a major cause of vision impairment. Nowadays, both central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) can be well-managed by intravitreal treatments. However, considering the long-life expectance of the patients, few data are present in the literature about the very long-term outcome of CRVO and BRVO. The present study was an interventional, retrospective analysis of the morphological and functional long-term outcome of CRVO and BRVO patients, followed in an Italian referral center. We collected data from 313 eyes (178 CRVO eyes and 135 BRVO eyes). Mean follow-up was 45 ± 25 months (range 12–84 months). Both CRVO and BRVO eyes experience a significant visual acuity improvement secondary to anti-vascular endothelial growth factor/dexamethasone treatments (from 0.57 ± 0.25 to 0.41 ± 0.24 LogMAR in CRVO and from 0.53 ± 0.42 to 0.30 ± 0.41 LogMAR in BRVO, respectively) (p < 0.01). Also, central macular thickness (CMT) resulted significant recovery at the end of the follow-up (from 585.54 ± 131.43 to 447.88 ± 245.07 μm in CRVO and from 585.54 ± 131.43 to 447.88 ± 245.07 μm in BRVO, respectively) (p < 0.01). CRVO eyes received a mean of 10.70 ± 4.76 intravitreal treatments, whereas BRVO underwent 9.80 ± 5.39 injections over the entire 7-year follow-up. Our analyses highlighted different time points indicating the best obtainable improvement. This was the first year for CRVO (12-month follow-up) and the second year for BRVO (24-month follow-up). After these two time points, both visual acuity and CMT resulted stable up to the end of the follow-up. Ischemia was associated with significantly worse outcome.

Keywords

central retinal vein occlusion - branch retinal vein occlusion - optical coherence tomography - real-life study - intravitreal injection

Volltext

Referenzen

References
1 Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117 (04) 429-441
2 Rogers S, McIntosh RL, Cheung N. et al; International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117 (02) 313-319
3 Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. Prog Retin Eye Res 2014; 41: 1-25
4 Noma H, Funatsu H, Sakata K. et al. Macular microcirculation and macular oedema in branch retinal vein occlusion. Br J Ophthalmol 2009; 93 (05) 630-633
5 Noma H, Funatsu H, Mimura T, Eguchi S, Hori S. Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. Am J Ophthalmol 2011; 152 (04) 669-677
6 Campochiaro PA, Brown DM, Awh CC. et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118 (10) 2041-2049
7 Kinge B, Stordahl PB, Forsaa V. et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 2010; 150 (03) 310-314
8 Haller JA, Bandello F, Belfort Jr R. et al; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117 (06) 1134-1146
9 Haller JA, Bandello F, Belfort Jr R. et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118 (12) 2453-2460
10 Heier JS, Campochiaro PA, Yau L. et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119 (04) 802-809
11 Campochiaro PA, Sophie R, Pearlman J. et al; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014; 121 (01) 209-219
12 Chatziralli I, Theodossiadis G, Chatzirallis A, Parikakis E, Mitropoulos P, Theodossiadis P. Ranibizumab for retinal vein occlusion: predictive factors and long-term outcomes in real-life data. Retina 2018; 38 (03) 559-568
13 Spooner K, Fraser-Bell S, Hong T, Chang AA. Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors. BMJ Open Ophthalmol 2019; 29 (04) e000249
14 Maggio E, Mete M, Maraone G, Attanasio M, Guerriero M, Pertile G. Intravitreal injections for macular edema secondary to retinal vein occlusion: long-term functional and anatomic outcomes. J Ophthalmol 2020; 2020: 7817542
15 Brown DM, Campochiaro PA, Singh RP. et al; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117 (06) 1124-1133
16 Boyer D, Heier J, Brown DM. et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012; 119 (05) 1024-1032
17 Brown DM, Heier JS, Clark WL. et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013; 155 (03) 429-437
18 Heier JS, Clark WL, Boyer DS. et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014; 121 (07) 1414-1420
19 Holz FG, Roider J, Ogura Y. et al. VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 2013; 97 (03) 278-284
20 Korobelnik JF, Holz FG, Roider J. et al; GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 2014; 121 (01) 202-208
21 Ogura Y, Roider J, Korobelnik JF. et al; GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 2014; 158 (05) 1032-1038
22 Battaglia Parodi M, Iacono P, Sacconi R, Parravano M, Varano M, Bandello F. Dexamethasone implant for macular edema secondary to central retinal vein occlusion in patients younger than 50 years. Retina 2015; 35 (07) 1381-1386
23 Larsen M, Waldstein SM, Priglinger S. et al; CRYSTAL Study Group. Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the CRYSTAL study. Ophthalmol Retina 2018; 2 (02) 134-142
24 Brown DM, Campochiaro PA, Bhisitkul RB. et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118 (08) 1594-1602
25 Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL. RAVE Study Group. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the Rubeosis anti-VEGF (RAVE) trial. Retina 2014; 34 (09) 1728-1735
26 Rezar S, Eibenberger K, Bühl W, Georgopoulos M, Schmidt-Erfurth U, Sacu S. Macula Study Group Vienna. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years. Acta Ophthalmol 2015; 93 (08) 719-725
27 Clark WL, Boyer DS, Heier JS. et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 2016; 123 (02) 330-336
28 Tadayoni R, Waldstein SM, Boscia F. et al; BRIGHTER study group. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 2016; 123 (06) 1332-1344
29 Tadayoni R, Waldstein SM, Boscia F. et al; BRIGHTER Study Group. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology 2017; 124 (12) 1778-1787
30 Battaglia Parodi M, Romano F, Arrigo A. et al. Real-life anti-vascular endothelial growth factor treatment for age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital. Eur J Ophthalmol 2020; 30 (06) 1461-1466
31 Chatziralli I, Theodossiadis G, Parikakis E, Mitropoulos PG, Theodossiadis P. Long-term anatomical and functional outcomes in patients with ischemic central retinal vein occlusion treated with anti-vascular endothelial growth factor agents. Ophthalmic Res 2017; 58 (04) 203-208
32 Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. Surv Ophthalmol 2018; 63 (06) 816-850